CareDx Stock Price, News & Analysis (NASDAQ:CDNA)

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDNA shares.
View CDNA analyst ratings or view top-rated stocks.

6 brokers have issued 12 month price targets for CareDx's shares. Their CDNA share price targets range from $9.00 to $25.00. On average, they predict the company's stock price to reach $13.80 in the next year. This suggests a possible upside of 40.7% from the stock's current price.
View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts.

CareDx's stock was trading at $11.41 at the start of the year. Since then, CDNA stock has decreased by 14.0% and is now trading at $9.81.
View the best growth stocks for 2023 here.

CareDx saw a decline in short interest in November. As of November 15th, there was short interest totaling 3,890,000 shares, a decline of 13.6% from the October 31st total of 4,500,000 shares. Based on an average daily trading volume, of 957,600 shares, the short-interest ratio is currently 4.1 days. Currently, 7.5% of the shares of the company are sold short.
View CareDx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our CDNA earnings forecast.

CareDx, Inc (NASDAQ:CDNA) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.06. The business had revenue of $67.19 million for the quarter, compared to analysts' expectations of $53.14 million. CareDx had a negative trailing twelve-month return on equity of 21.94% and a negative net margin of 30.46%. The firm's revenue was down 15.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.32) EPS.

ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Genomics & Biotechnology ETF (GNOM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

CareDx updated its FY 2023 earnings guidance on Wednesday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $274.00 million-$278.00 million, compared to the consensus revenue estimate of $255.42 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

CareDx's stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.33%), Sumitomo Mitsui Trust Holdings Inc. (5.58%), Armistice Capital LLC (3.76%), Kent Lake Capital LLC (2.54%), Jacobs Levy Equity Management Inc. (2.08%) and First Eagle Investment Management LLC (1.86%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends.

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.